Yahoo Finance Today's Research Reports on Trending Tickers: Immunomedics and FibroGen
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Major U.S. equities finished moderately lower on Wednesday with the Dow Jones dropping over 300 points after minutes from the Federal Reserve September’s meeting showed that central bank remains convinced it needs to tighten monetary policy. But the market closed well off its lows as investors grappled with a flood of corporate earnings. The Dow Jones Industrial Average shed 0.36 percent to close at 25,706.68, while the S&P 500 Index decreased 0.03 percent to close at 2,809.21. The Nasdaq Composite Index declined 0.04 percent to close at 7,642.70.
According to Lindsey Bell investment strategist with CFRA, “The market is interpreting the Fed minutes as slightly hawkish.” For a moment, market participants didn’t believe the Fed was serious about increasing rates four times in 2018 and thrice in 2019, she said. However that changed after hawkish comments from Fed Chairman Powell earlier October. “The FOMC minutes are another reminder that the Fed is serious, and isn’t going to let President Trump bully them” to a more dovish outlook, said Bell.
RDI Initiates Coverage on:
Immunomedics, Inc.
https://rdinvesting.com/news/?ticker=IMMU
FibroGen, Inc.
https://rdinvesting.com/news/?ticker=FGEN
Immunomedics' stock jumped 4.68% Wednesday, to close the day at $22.35. The stock recorded a trading volume of 1,820,564 shares, which was above its three months average volume of 1,592,656 shares. In the last year, Immunomedics' shares have traded in a range of 8.68 - 27.33. The share price has gained 157.49% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $22.47 is above its 200-day moving average of $21.75. Shares of Immunomedics have fallen roughly 0.84 percent in the past month and are up 38.3 percent year-to-date.
Access RDI's Immunomedics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IMMU
On Wednesday, shares of FibroGen recorded a trading volume of 501,336 shares, which was above the three months average volume of 426,581 shares. The stock ended the day 4.11% higher at $55.72. The share price has fallen 18.72% from its 52 week high with a 52 week trading range of 40.74 - 68.55. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $57.51 is above its 200-day moving average of $56.59. Shares of FibroGen have fallen roughly 1.9 percent in the past month and are up 17.55 percent year-to-date.
Access RDI's FibroGen, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=FGEN
Our Actionable Research on Immunomedics, Inc. (NASDAQ:IMMU) and FibroGen, Inc. (NASDAQ:FGEN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
